Last checked at 21 Jan 2021 20:12
DIRECTOR DEALINGS SUMMARY: New U&I Group CEO Upton Buys Shares
DIRECTOR DEALINGS SUMMARY: New U&I Group CEO Upton Buys Shares
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Shield Thera Share News (STX)
STX Share
Price
STX Share
News
STX Share
Chat17
STX Share
Trades68
STX
Live RNS
STX Share
Charts
STX Level 2
Console
STX Live
Share Price
STX Broker
Ratings
STX Directors
Deals
STX Financial
Diary
STX
Fundamentals
STX Short
Positions
STX
Media
Shield Thera Information
Share Price Information for Shield Thera (STX)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1.35
Bid:
1.30
Ask:
1.40
Change:
0.125 (10.20%)
Spread:
0.10 (7.692%)
Open:
1.225
High:
1.35
Low:
1.20
Prev. Close:
1.225
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.19 Jan 2021 15:04
DIRECTOR DEALINGS: Shield Therapeutics CEO Buys 100,000 Shares
DIRECTOR DEALINGS: Shield Therapeutics CEO Buys 100,000 Shares
Read more15 Jan 2021 13:11
IN BRIEF: Shield Therapeutics Expects Increase In Annual Revenue
IN BRIEF: Shield Therapeutics Expects Increase In Annual Revenue
Read more14 Dec 2020 16:59
UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares
UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares
Read more11 Dec 2020 16:40
IN BRIEF: Shield Therapeutics Shares Drop As Eyes US Push On Its Own
IN BRIEF: Shield Therapeutics Shares Drop As Eyes US Push On Its Own
Read more19 Oct 2020 17:34
IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition
IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition
Read more19 Oct 2020 09:12
Shield shares rise as Teva withdraws patent oppositions
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on its opposition proceedings with Teva Pharmaceutical Industries on Monday, confirming that Teva had withdrawn its appeal and opposition over two of Shield's patents.
Read more16 Sep 2020 11:13
Shield Therapeutics Swings To Profit As It Makes Feraccru Progress
Shield Therapeutics Swings To Profit As It Makes Feraccru Progress
Read more7 Aug 2020 06:56
IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia
IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia
Read more16 Jul 2020 21:19
IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication
IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication
Read more26 Jun 2020 17:19
UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down
UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down
Read more11 Jun 2020 16:17
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read more3 Jun 2020 15:57
Shield Therapeutics shares rise on two recent research papers
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics reported the recent publication of two papers concerning its 'Feraccru' or 'Accrufer' product on Wednesday.
Read more26 May 2020 14:22
UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield
UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield
Read more26 May 2020 08:58
Shield Therapeutics names Hans Peter Hasler as next chairman
(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.
Read more